ZTS

Zoetis stock declined 1.18% to $81.03, underperforming the S&P 500's 0.52% loss. Despite a strong 16.69% monthly gain, the company faces headwinds with projected Q3 EPS down 11.18% and full-year earnings expected to decline 4.21%. The stock holds a Zacks Rank #4 (Sell) rating, though it trades at a valuation discount to its industry peers.

Zoetis (ZTS) and ImmuCell (ICCC) operate in animal health but with different profiles. Zoetis offers diversification across companion animals, livestock, and diagnostics but faces near-term headwinds from declining companion animal demand and reduced 2026 guidance. ImmuCell shows stronger recent growth with 20.9% sales increases and expanding market share in calf scours prevention, but carries higher execution risks due to narrow product focus and margin pressures during manufacturing expansion.

Zoetis (ZTS) gained 2.37% in the latest session, outperforming the S&P 500's 0.6% gain. However, the animal health company faces headwinds with forecasted EPS declining 10.59% and revenue expected to drop 3.66% in the upcoming quarter. The stock holds a Zacks Rank of #4 (Sell) with no recent estimate revisions, and trades at a Forward P/E of 11.78, below its industry average.

Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results.

Vietnam's veterinary vaccine import market is expanding due to growing livestock and aquaculture sectors, with imports valued at US$172 million in 2024. The market remains highly dependent on imported vaccines, particularly from the US (34.6%), China (12.8%), and Netherlands (8.7%). International companies like Zoetis, MSD Animal Health, and Boehringer Ingelheim maintain strong positions, while foreign investment opportunities are emerging through joint ventures and local manufacturing partnerships.

Zoetis (ZTS) ended trading at $69.10, down 1.05% from the previous day and 8.32% over the past month. The animal health company faces a negative earnings outlook with forecasted EPS down 10.59% and revenue down 3.66% for the upcoming quarter. The stock has been assigned a Zacks Rank of #5 (Strong Sell), though it trades at a discount to its industry average with a Forward P/E of 11.26.

Europe's companion animal diagnostics market is projected to reach US$2.27 billion by 2031, growing at a 9.5% CAGR from 2024-2031. Growth is driven by AI-enabled testing, preventive pet care adoption, technological advancements, and rising pet insurance uptake.

Germany and the UK lead the market, with veterinary hospitals and clinics as the largest end-user segment. Key players are investing in product development and AI integration to enhance diagnostic capabilities.

The global veterinary diagnostics market is projected to grow from USD 11.76 billion in 2025 to USD 30.78 billion by 2035, driven by increasing pet ownership, zoonotic disease surveillance, and advancements in point-of-care testing and molecular diagnostics. North America leads with 39% market share, while Asia-Pacific shows the fastest growth. Reagents & kits dominate products, while companion animals represent 61% of the market.